BeyondSpring Stock
BeyondSpring Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Qiu Min
- Employees
- 44
- Market cap
- $23 M
- IPO
- 09/03/2017
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the…
BeyondSpring stock: price history
1D
-3.9%
1W
-7.7%
1M
-21.1%
6M
-67.7%
YTD
-65.7%
1Y
-68.8%
2Y
-76.6%
5Y
-96.6%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~17% stronger price swings than usual
Ask the agents about BeyondSpring
Analyst assessment of BeyondSpring
0
STRONG BUY
6
BUY
2
HOLD
1
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 02/05/2023
BeyondSpring stock metrics
P/E
-3.39
P/B
-0.65
EV/EBITDA
-2.6
RETURN ON EQUITY
2.4%
NET MARGIN
0.0%
DEBT/EQUITY
-0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.7%
FLOAT SHARES
31,950,100
AVG. DAILY VOLUME (30D)
431,673
Insider transactions (SEC)
Huang Lan
Institutional holders
Comparable stocks
Frequently asked questions about BeyondSpring stock
What does BeyondSpring do?
BeyondSpring Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Qiu Min, the company employs around 44 people.
The IPO was on 09/03/2017; the stock trades on NASDAQ under the ticker BYSI.
What do analysts say about BeyondSpring stock?
9 analysts rate the stock, the consensus is Buy (as of 02/05/2023).
This is an external assessment, not a statement by Market Jury.
When does BeyondSpring report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 17% stronger than usual.
Does BeyondSpring pay a dividend?
No, BeyondSpring currently does not pay a dividend.
Which stocks are comparable to BeyondSpring?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BeyondSpring stock analyzed?
Clicking "Analyze stock" lets five strategies assess BeyondSpring against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.